Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents

Exclusion Criteria

• •Anemia due to a cause other than CKD
• •Active bleeding or recent clinically significant blood loss
• •Treatment with an erythropoiesis-stimulating agents (ESA) within 8 weeks prior to Screening
• •History of sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia
• •Red Blood Cells transfusion within 4 weeks
• •Serum albumin level \<2.5 g/dL
• •Uncontrolled hypertension
• •Active malignancy or treatment for malignancy within the past 2 years prior to Screening
• •Evidence of iron overload or diagnosis of hemochromatosis
• •Known hypersensitivity to vadadustat or any excipients in vadadustat tablet